UK +44 (0)1865 849841
Malaysia +603 2779 0098

Liquid Biopsies

Circulating biomarkers in melanoma immunotherapy

Genevieve Boland, speaking at the Research & Technology Series, described the translational research conducted at her laboratory. Using tumour and blood samples from patients before treatment, at meaningful clinical changes, progression, and post-mortem she, and her team are trying to understand the biology of Melanoma to treat patients better.

Read More

Multiplex Super-Selective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations

Professor Fred Kramer spoke at the recent Research & Technology Series exploring Flow Cytometry / qPCR & Digital PCR / Liquid Biopsies. During his presentation, he explained how Super Selective primers enable the simultaneous identification and quantitation of rare somatic mutations in routine multiplex PCR assays, while virtually eliminating signals from abundant closely related wild-type sequences.

Read More

How to translate biomarker discoveries into clinical applications

Extracellular vesicles provide an exciting opportunity as a modality for non-invasive biomarkers, which may enable them to be used as biomarkers for tumour metastasis.  

Read More

ctDNA and AI are the way forward in early cancer detection and metastatic treatment

We spoke with Dr David Guttery about his pioneering work using circulating tumour DNA to enable early detection, monitoring and therapeutic decision making for better patient outcomes in gynaecological cancers.

Read More

Diverse Approaches in Immuno-Oncology: A Review of the Research & Technology Series

This blog was published on Clarivate’s Cortellis blog. It is reproduced here with their kind permission.

A fascinating range of insights into the ways in which the immune system can be harnessed to fight cancer was provided by Global Engage’s Immuno-Oncology Research & Technology Series meeting held in October in London. The conference comprised five concurrent tracks covering cutting-edge developments in fields such as cell therapies, novel antibodies and neoantigens. Some of the highlights tracked by the Cortellis team are presented below.

Read More

The Liquid Biopsy Workflow

Anders Stahlberg works both in the academic setting as Associate Professor at the University of Gothenburg and in the clinical setting at Clinical Genetics & Genomics, Sahlgrenska University Hospital. Together with his colleagues, this means all aspects of circulating cell-free tumour DNA are covered; from basic science and development, understanding why and how liquid biopsies should be undertaken, to clinically focused questions that the patient will hopefully benefit from.

Ahead of the Liquid Biopsies Congress later this year, we spoke to him about his work.

Read More

Strategic screening enables effective biomarker discovery

During my eight years at the Max Planck Institute for Molecular Genetics in Berlin, I led a protein technologies group. We developed a protein expression library, and then high-content protein arrays. In total, we made arrays with 10,000 different human proteins.

Read More

Why do biomarkers fail?

When conducting an experiment to identify biomarkers, it is crucial to design the experiment properly. 80-90% of all biomarker populations for the last 20 years have not and cannot be reproduced, and the main reason that biomarkers fail is that these experiments are not designed properly. In this post, I will outline two ways in which experiments are poorly designed, and then outline the technological and methodological solution in a later blog.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Archive